Abstract
This study aimed to improve the pH-independent solubility and dissolution characteristics of valsartan via the preparation of solid dispersions (SD) with poloxamer 407. SDs was prepared by using the solvent method at various drug-polymer ratios and their dissolution characteristics were examined at different pHs. Oral pharmacokinetics of SDs was also evaluated in rats. Compared to the untreated powder, SDs significantly improved the dissolution rate as well as the extent of drug release at low pH. Particularly, SD having the drug-polymer ratio of 1:5 exhibited pH-independent dissolution of valsartan, resulting in the rapid and complete drug release over the pH range of 1.2 to 6.8. The improved dissolution of valsartan via SD formulation appeared to be well correlated with the enhanced oral exposure of valsartan in rats. SDs increased Cmax and AUC0–24 of valsartan by 2–7 folds in rats, implying that SDs should be effective to improve the bioavailability of valsartan. In conclusion, SDs containing poloxamer 407 appeared to be effective to improve the pH-independent dissolution and oral absorption of valsartan.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahuja, N., Katare, O. P., and Singh, B., Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Eur. J. Pharm. Biopharm., 65, 26–38 (2007).
Attwood, D., Collett, J. H., and Tait, C. J., The micellar properties of the poly(oxyethylene) — poly(oxypropylene) copolymer Pluronic F127 in water and electrolyte solution. Int. J. Pharm., 26, 25–33 (1985).
Chutimaworapan, S., Ritthidej, G. C., Yonemochi, E., Oguchi, T., and Yamamoto, K., Effect of water-soluble carriers on dissolution characteristics of nifedipine solid dispersions. Drug Dev. Ind. Pharm., 26, 1141–1150 (2000).
Criscione, L., de Gasparo, M., Buhlmayer, P., Whitebread, S., Ramjoue, H. P., and Wood, J., Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br. J. Pharmacol., 110, 761–771 (1993).
Dumortier, G., Grossiord, J. L., Agnely, F., and Chaumeil, J. C., A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm. Res., 23, 2709–2728 (2006).
Flesch, G., Muller, P., and Lloyd, P., Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur. J. Clin. Pharmacol., 52, 115–120 (1997).
Kim, E. J., Chun, M. K., Jang, J. S., Lee, I. H., Lee, K. R., and Choi, H-K., Preparation of a solid dispersion of felodipine using a solvent wetting method. Eur. J. Pharm. Biopharm., 64, 200–205 (2006).
Leuner, C. and Dressman, J., Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm., 50, 47–60 (2000).
Mbah, C. J., Physicochemical properties of valsartan and the effect of ethyl alcohol, propylene glycol and pH on its solubility. Pharmazie, 60, 849–850 (2005).
Mbah, C. J., Solubilization of valsartan by aqueous glycerol, polyethylene glycol and micellar solutions. Pharmazie, 61, 322–324 (2006).
Newa, M., Bhandari, K. H., Kim, J. O., Im, J. S., Kim, J. A., Yoo, B. K., Woo, J. S., Choi, H. G., and Yong, C. S., Enhancement of solubility, dissolution and bioavailability of ibuprofen in solid dispersion systems. Chem. Pharm. Bull., 56, 569–574 (2008).
Patel, A. R. and Joshi, V. Y., Evaluation of SLS: APG mixed surfactant systems as carrier for solid dispersion. AAPS PharmSciTech, 9, 583–590 (2008).
Rao, V. M., Engh, K., and Qiu, Y., Design of pH-independent controlled release matrix tablets for acidic drugs. Int. J. Pharm., 252, 81–86 (2003).
Riis, T., Bauer-Brandl, A., Wagner, T., and Kranz, H., pHindependent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations. Eur. J. Pharm. Biopharm., 65, 78–84 (2007).
Singh-Joy, S. D. and McLain, V. C., Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int. J. Toxicol., 27, 93–128 (2008).
Tran, P. H., Tran, H. T., and Lee, B. J., Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release. J. Control. Release, 129, 59–65 (2008).
Vasconcelos, T., Sarmento, B., and Costa, P., Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today, 12, 1068–1075 (2007).
Yamada, I., Goda, T., Kawata, M., Shiotuki, T., and Ogawa, K., Gastric acidity-dependent bioavailability of commercial sustained release preparations of indomethacin, evaluated by gastric acidity-controlled beagle dogs. Chem. Pharm. Bull., 38, 3112–3115 (1990).
Yu, J., Chun, M-K., and Choi, H-K., Preparation and characterization of piroxicam/poloxamer solid dispersion prepared by melting method and solvent method. J. Kor. Pharm. Sci., 37, 1–5 (2007).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Park, Y.J., Lee, HK., Im, Y.B. et al. Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion. Arch. Pharm. Res. 33, 1235–1240 (2010). https://doi.org/10.1007/s12272-010-0814-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-010-0814-0